Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual Event

Sep 28, 2020 2:00 PM - Sep 30, 2020 6:00 PM

(Central Europe Standard Time)

4051 Basel, Switzerland

Regulatory Science Forum

Session 4: Body of Evidence

Session Chair(s)

Anne  Morant, PhD, MSc

Anne Morant, PhD, MSc

Regulatory Science Specialist, freelance

Anne Morant Consulting, Denmark

Session Overview: The ‘Body of Evidence’ session will revolve around generation of substantial evidence of clinical efficacy to support approval of new medicines. With focus on EMA and FDA, the presenters will share results of their regulatory science research on topics such as approvals based on a single pivotal trial; demonstration of clinical relevance; as well as pre- and post-approval evidence pertaining to use of expedited pathways.

Speaker(s)

Petra  Sevcikova

Systematic analysis of evidence supporting expedited approvals by the EMA 2011-2018 and fulfilment of post-marketing obligations

Petra Sevcikova

Newcastle University, United Kingdom

Honorary Senior Researcher, Centre for Regulatory Science

Lourens  Bloem, PharmD, PhD, MSc

Clinical Value Of Oncology Medicines In Europe: Is It Different For Conditionally Approved Medicines?

Lourens Bloem, PharmD, PhD, MSc

Utrecht University, Netherlands

Assistant Professor Clinical Therapeutics

Katrine  Schultz-Knudsen, MSc

Providing Substantial Evidence with a single pivotal trial: Discussion of Regulatory trends in the EU and US

Katrine Schultz-Knudsen, MSc

H. Lundbeck A/S, Denmark

Graduate

João  Duarte, MPharm, MSc

Clinical relevance: an analysis of EMA and FDA Advisory Groups in support of new Marketing Authorisation applications between 2011 and 2015

João Duarte, MPharm, MSc

Ipsen, France

Vice President, Global Regulatory Affairs Excellence

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.